文献速递银屑病与炎症性皮肤病

儿童重症银屑病系统治疗的药物生存率:国际回顾性研究

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-10-17

该国际多中心回顾性ACMe队列纳入506例接受683次治疗的儿童重症银屑病患者,比较阿维A、甲氨蝶呤和环孢素的2年药物生存率。阿维A与甲氨蝶呤中位生存期相似(10.8 vs 10.9个月),均优于环孢素(3.9个月,p<0.0001)。阿维A一线使用时生存期更长,不良反应是常见停药原因。

要点

  • 阿维A与甲氨蝶呤2年药物生存率相当,均优于环孢素。
  • 环孢素最常见停药原因为无效(43.0%),阿维A和甲氨蝶呤为疗效丧失。
  • 阿维A一线使用中位生存期11.3个月,优于后线5.5个月(p<0.001)。

核心结论

  • 阿维A与甲氨蝶呤的2年药物生存率相当,且均优于环孢素。
  • 除阿维A一线使用外,未发现其他预测治疗维持的因素。
  • 不良反应是停药的常见原因,甲氨蝶呤组报告1例严重不良反应(肝炎)。

研究设计与样本

  • 国际、多中心、回顾性、真实世界ACMe队列研究。
  • 纳入2014至2024年接受治疗的儿童重症银屑病患者,共506例患者接受683次治疗。

主要发现

  • 阿维A、甲氨蝶呤和环孢素的中位2年药物生存期分别为10.8个月、10.9个月和3.9个月(环孢素vs其他,p<0.0001)。
  • 环孢素停药最常见原因为无效(43.0%),阿维A和甲氨蝶呤为疗效丧失(27.2%和31.8%)。
  • 阿维A一线治疗中位生存期11.3个月,后线治疗5.5个月(p<0.001);甲氨蝶呤和环孢素无此差异。
  • 因不良事件停药的比例:阿维A 13.8%,甲氨蝶呤23.1%,环孢素14.0%(p=0.02)。
  • 仅报告1例严重不良事件:甲氨蝶呤组肝炎。

临床怎么用

  • 结果可帮助制定儿童银屑病系统治疗算法。
  • 阿维A和甲氨蝶呤可作为优先考虑的系统治疗选择。
  • 环孢素因生存期较短,可能更适合短期使用。
  • 阿维A一线使用可能提高治疗维持率。

局限性

  • 回顾性研究设计。
  • 未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Three conventional systemic treatments, acitretin, methotrexate and cyclosporine, are used for severe childhood psoriasis. In many countries, they are the only treatments available. There are limited data and no comparative evaluations of these treatments. OBJECTIVES: The international, multicentre, retrospective, real-world ACMe cohort was developed to assess the comparative 2-year drug survival of acitretin, methotrexate and cyclosporine in paediatric psoriasis. METHODS: Thirty dermatology centres in France, Italy, Portugal, Canada and the United Kingdom participated in the study. Demographic and clinical data were collected using a standardized form for patients receiving treatment from 2014 to 2024. RESULTS: A total of 506 patients received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin (10.8 months) and methotrexate (10.9 months), but lower for cyclosporine (3.9 months; p < 0.0001). The most common reasons for discontinuation were inefficacy for cyclosporine (43.0%), and loss of effectiveness for acitretin (27.2%) and methotrexate (31.8%). No demographic, clinical or therapeutic characteristics were associated with higher rates of treatment maintenance at 6 months. Drug survival was higher for acitretin when used as a first-line therapy (median drug survival: 11.3 months for first-line vs. 5.5 months for second- or subsequent-line therapy; p < 0.001), but there were no differences for methotrexate and cyclosporine. Adverse events (AEs) were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine (p = 0.02). Only one serious AE was reported: hepatitis in the methotrexate group. CONCLUSIONS: This cohort study showed that acitretin and methotrexate had comparable 2-year drug survival rates, which were superior to cyclosporine. We did not find any predictive factors for increased treatment maintenance except for first-line use of acitretin. AEs were a frequent reason for discontinuing treatments. These results may help develop treatment algorithms for systemic therapy in paediatric psoriasis. Severe forms of psoriasis may require the use of general treatments. Three usual treatments (acitretin, methotrexate and cyclosporine) are used for severe childhood psoriasis. In many countries, they are the only treatments available. In this international, multicentre, retrospective study, we compared the 2‐year drug survival (duration before stopping treatment) of these treatments in paediatric psoriasis. Thirty dermatology centres from five countries included 506 patients who received 683 treatments: acitretin (n = 316), methotrexate (n = 245) and cyclosporine (n = 122). Median drug survival at 2 years was similar for acitretin and methotrexate, but lower for cyclosporine. The most common reasons for discontinuation were inefficacy for cyclosporine and loss of effectiveness for acitretin and methotrexate. We did not identify demographic, clinical or therapeutic characteristics associated with higher rates of treatment maintenance at 6 months. Adverse events were the reason for stopping treatment in 13.8% of patients on acitretin, 23.1% on methotrexate and 14.0% on cyclosporine. This study showed that acitretin and methotrexate had comparable 2‐year drug survival rates, which were superior to cyclosporine. These results may help develop treatment algorithms for systemic therapy in pediatric psoriasis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Miao Y, Beauchet A, Piram M, et al. Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study. J Eur Acad Dermatol Venereol. 2025. PMID: 41104794. doi:10.1111/jdv.70108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。